Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. USO
10. NVDA

Go back to Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

Lexicon Pharma (LXRX) to Resume Trading at 7:45 a.m.

July 30, 2020 7:42 AM EDT

Lexicon Pharma (NASDAQ: LXRX) to Resume Trading at 7:45 a.m.

... More